IL6 and breast cancer: Moreover, lower expression of syndecan-1 in the triple negative SUM-149 cell line shows concomitantly reduced expression of interleukin-6 (IL-6), interleukin-8 (IL-8), and epithelial growth factor receptor (EGFR) with definitive effects for the formation of the aggressive inflammatory BC phenotype [32].